Industry insiders point out that the continuous expansion of the health product market, driven by the introduction and deepening of new products, is one of the main driving forces behind the growth of the health product packaging market. Currently, domestic health product packaging companies have completed capacity expansion, and a new round of industry competition has begun. The compatibility of pharmaceutical packaging is the primary challenge that Chinese health product packaging factories should overcome. Developing new products, optimizing product structure, and implementing energy-saving and emission-reduction technological transformations to reduce product costs have become essential breakthroughs for enterprises.

Industry chaos, enterprise difficulties

In recent years, China's health product packaging industry has maintained an average annual growth rate of over 10%, and its total output value has accounted for more than 10% of the national packaging industry's total output value, higher than the proportion of the pharmaceutical industry in the national industrial output value. However, the overall strength of China's pharmaceutical packaging materials industry is still relatively weak, with mostly small-scale enterprises and low management levels. There is serious low-level duplication of low-end products, insufficient development and application of new products and technologies, and the quality standards and system construction are still not sound.

Unreasonable structure, insufficient product grade, weak innovation ability, and talent shortage are currently prominent problems in the pharmaceutical packaging materials industry. Tight funding, financing difficulties, and fierce market competition further hinder the development and growth of enterprises.

According to relevant information from the China Health Product Packaging Portal (www.yybzok.com), there are currently thousands of health product packaging companies in China, capable of producing more than 90% of packaging materials. However, most of them are small-scale, with low technology and management levels, and serious low-level duplication of low-end products. The decline in the net profit of packaging companies is mainly due to the partial production restrictions imposed by downstream pharmaceutical companies, the rising prices of upstream resource-type raw materials and chemical products, and disorderly competition within the industry.

However, where there are shortcomings, there are opportunities.

Compatibility research promotes industrial upgrading. The "Twelfth Five-Year" plan for the health product packaging industry will bring many previously unregulated contents under supervision, requiring pharmaceutical companies to pay more attention to the compatibility of packaging materials. This presents a rare opportunity for health product packaging companies.

According to the new regulations, packaging compatibility will be a key focus for regulatory authorities in 2012. It is understood that after drugs are packaged, migration, penetration, corrosion, and adsorption may occur, affecting drug quality. Compatibility testing is designed to examine whether these phenomena occur between pharmaceutical packaging materials and drugs, aiming to ensure drug safety, effectiveness, and uniformity. Pharmaceutical companies and packaging material manufacturers need to put more effort into pharmaceutical compatibility testing to better guide and promote the application of higher-quality and safer pharmaceutical packaging materials and solve various problems encountered in the practical application of upgraded packaging materials.

“At present, the understanding and research of pharmaceutical packaging materials and drug compatibility among enterprises is still relatively weak. Enterprises urgently need to improve their business research level to align with the requirements and concepts of the new GMP,” experts point out.

Email:

190022044@qq.com

Phone:

+8615863109077

Address:

Nan, Qili Shui Tou Residents' Committee, Wendeng District, Weihai City